The trial includes 48 patients with non-active secondary progressive multiple sclerosis (na-SPMS) across the U.S. ・The ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial ...

Foralumab may help slow disability progression and ease fatigue in people with nonactive SPMS, per data from an early access ...

Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue.BOSTON, May 19, 2026 ...

Detailed price information for Tiziana Life Sciences Ltd (TLSA-Q) from The Globe and Mail including charting and trades.

Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed In response to an FDA request, Sanofi has submitted an ...

Secondary progressive multiple sclerosis (SPMS) can develop after relapsing-remitting multiple sclerosis (RRMS). It causes steady neurological decline, either with or without relapses. Switching from ...